Free CME

Primary care clinicians and endocrinologists play a critical role in identifying and managing metabolic dysfunction-associated steatohepatitis (MASH) before it progresses. Results from a Med-IQ survey, however, revealed that approximately half of the respondents screen only 50% or fewer of their patients with obesity or type 2 diabetes. Patients with these conditions or other risk factors, such as metabolic syndrome, dyslipidemia, or elevated liver enzymes, should be screened using noninvasive tools like FIB-4, transient elastography (FibroScan), ELF, or VCTE.

Although lifestyle modification remains the cornerstone of treatment, pharmacologic options such as GLP-1 receptor agonists, pioglitazone, and resmetirom may be appropriate based on individual risk profiles. Most patients can be effectively managed in primary care or endocrinology settings, with hepatology referral recommended for patients with a high risk of advanced fibrosis.

The therapeutic landscape for diabetic macular edema (DME) is rapidly evolving with the introduction of novel treatments, protocols, and delivery methods designed to improve visual outcomes and reduce patient burden. Advancements include extended injection protocols that are the result of longer durations of action for recently approved therapies and the Port Delivery System with ranibizumab—a sustained drug delivery system that was approved in February of 2025 for the treatment of patients with DME. In this Rapid Response activity, experts in the field discuss the latest clinical reports on the treatment of DME as presented at the Angiogenesis 2025 meeting. Faculty engage in a fast-paced review of the latest data on DME treatments, protocols, and modalities and discuss how these updates affect their own clinical practices and the broader field of retinal care.

In this online, self-learning activity:

Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia B is the same across race and ethnic groups, affecting approximately 1 out of every 30,000 male births.

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment from the ACC 2025 annual meeting.

In this online, self-learning activity:

Thalassemias belong to a group of recessively inherited blood disorders characterized by little or no hemoglobin production and chronic anemia of varying severity. Alpha thalassemia (AT) is most commonly found in people of Mediterranean, Middle Eastern, Asian, and North African descent. Worldwide, 5% of people are AT carriers, with a much higher prevalence in certain regions (e.g., up to 23% in Southeast Asia). AT is typically caused by deletions of one or more α-globin genes, leading to reduced or abolished α-globin production; non-deletional forms of AT can also occur and are generally more severe. The loss of functional α-globin disrupts the globin chain equilibrium, leading to excess γ- and β-globin chain formation and causing ineffective erythropoiesis. Patients with both deletional and non-deletional types of AT can develop various clinical complications, such as iron overload, gallstones, impaired liver function, osteoporosis, and elevated uric acid levels. Cardiopulmonary and skeletal deformities are common in patients from countries in the Western hemisphere who have elevated ferritin, while infections are the leading complication and cause of death in patients who live in countries in the Eastern hemisphere and have transfusion-dependent thalassemia.

Uveitic macular edema (UME) is the leading cause of visual impairment in patients with uveitis, particularly in patients with noninfectious uveitis. Noninfectious uveitis affects up to 30% of patients with uveitis and can lead to vision-threatening complications, such as macular ischemia, if left untreated. Corticosteroids remain the first-line treatment, delivered via systemic, periocular, or intravitreal routes, but their long-term use is limited by significant ocular and systemic adverse effects. Advances in treatment, such as long-acting intravitreal corticosteroid implants, immunomodulatory therapies, and novel delivery systems like suprachoroidal injections, have improved outcomes by reducing adverse effects and enhancing visual acuity and macular anatomy. Despite these advancements, treatment regimens remain challenging due to limited robust evidence, variability in patient response, and adverse event profiles. In this CE activity, expert faculty compare corticosteroid delivery systems based on dosage, administration, and the ability to personalize treatment. They also review the latest clinical evidence for UME treatments and their ability to improve long-term outcomes.

In this online, self-learning activity:

Nasopharyngeal carcinoma (NPC) is a rare form of head and neck cancer, with 133,000-176,000 new cases diagnosed worldwide each year. Although relatively uncommon in the United States with an age-standardized incidence rate of 0.41 per 100,000 population, NPC is endemic to certain geographic regions, such as southern China, Southeast Asia, and North Africa. Several risk factors for NPC have been identified, including consumption of salted fish, alcohol use, wood dust exposure, and plasma Epstein–Barr virus positivity.

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment presented at the HFSA Annual Scientific Meeting 2025 and AHA Scientific Sessions 2025.

In this online, self-learning activity:

Chronic lymphocytic leukemia (CLL) is a disease in which leukemic cells accumulate in the peripheral blood, bone marrow, and lymphatic tissue. Elderly patients comprise the vast majority of those diagnosed with CLL with a mean patient age of 72 years. There are over 23,000 cases in the U.S. per year, with an annual mortality rate in excess of 4,400. CLL may have an indolent disease course and go undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy (the most common), night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by cytogenetic abnormalities and earlier progression of disease. Both the presentation and progression of CLL vary between patients, although patients with very-high-risk disease have a median survival of 19 months and a five-year overall survival of less than 24%.

Patients with retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) face significant challenges with current anti-vascular endothelial growth factor (VEGF) therapies, including frequent intravitreal injections, which disrupt daily life and contribute to poor adherence and suboptimal outcomes. These burdens are compounded by systemic management needs, psychological distress, and financial costs. Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and providing sustained-release options to reduce injection frequency. Data from ongoing TKI studies show encouraging results in improving durability, adherence, and visual outcomes. While no TKIs are currently approved for retinal diseases, these therapies are advancing through clinical trials, potentially transforming treatment paradigms. In this CE activity, expert faculty summarize the challenges associated with anti-VEGF use, review the rationale for targeting tyrosine kinases in nAMD and DR, and summarize the most recent clinical trial data on TKIs.

In this online, self-learning activity:

Lung cancer is the leading cause of cancer-related death in the United States, with more than 236,000 new cases diagnosed and over 124,000 deaths annually. The most common type of lung cancer, non–small cell lung cancer (NSCLC), accounts for about 85% of cases and has seen steady declines in mortality over the past several years as improvements have been made in diagnosis, staging, and treatment. In contrast, outcomes for the less prevalent small cell lung cancer (SCLC), which is neuroendocrine in nature and accounts for about 14% of all lung cancer cases, have remained poor in recent years despite improvement in those for NSCLC.

This on-demand webinar provides a comprehensive overview of Pain Reprocessing Therapy, Emotional Awareness and Expression Therapy, and related approaches. Led by Yoni K. Ashar, PhD, this course explores the key distinctions between pain recovery therapies and traditional pain management, offering practical tools to help patients achieve lasting relief.

Physicians, psychologists, and healthcare professionals will benefit from this evidence-based training, earning 1 CME or CEU upon completion.

Effective treatment of glaucoma is crucial to prevent vision loss and preserve quality of life in affected patients. This CME program explores the medical management of glaucoma using Rho kinase inhibitors (ROCKis) to lower intraocular pressure (IOP) and reduce episcleral venous pressure. Experts will review clinical and real-world data on ROCKi-based regimens, comparing monotherapy and combination approaches for IOP reduction. Clinical cases will illustrate the practical application of ROCKi in daily practice, exploring strategies to improve outcomes for patients with glaucoma.

Pri-Med is committed to supporting you in meeting the Drug Enforcement Administration (DEA) CME training requirements under the MATE Act. The free CME courses offered here focus on opioid and substance use disorders and can be combined in any way to complete the eight-hour training mandate. 

This CME program is designed to enhance neurologists’ understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden can inform clinical decision-making and improve individualized care. The program will also examine the pathophysiology of gMG, emphasizing how this guides treatment selection. The limitations of current standard-of-care therapies will also be explored. Participants will review the latest clinical evidence surrounding neonatal Fc receptor (FcRn) inhibitors, including their role in addressing underlying disease processes and supporting long-term management strategies. By integrating all of these insights, neurologists will be better equipped to optimize patient outcomes and achieve sustained disease control in individuals with gMG.

This brief accredited CME activity uses a quiz-based microlearning platform to present a patient case scenario and related questions, allowing clinicians to quickly test their knowledge of the essential components of evaluating patients with metastatic colorectal cancer to the liver and selecting an appropriate treatment strategy. They can then compare their responses with those of their peers. Rationale for correct answers and key educational takeaways are provided via video clips from expert faculty.

This 30-minute Symposium from the 2025 Fall Clinical Dermatology Conference for PAs and NPs explores how to personalize psoriasis management and improve treatment selection based on patient specific history.

“With biologics we have gotten more specific. Before we had this big sweeping sword and now we have these precise, tiny knives. That is where we are at with going from previous agents to IL-23 and IL-17 blockers.” – Dr. Harrison Nguyen.

This activity is supported by educational grants from AbbVie, Johnson & Johnson and Ortho Dermatologics, and SUN Pharmaceutical Industries, Ltd.

In this online, self-learning activity:

Human immunodeficiency virus (HIV) is a retrovirus that preferentially targets CD4+ T lymphocytes, driving chronic immune activation, CD4+ depletion, and heightened vulnerability of people living with it (PLWH) to opportunistic infections and certain malignancies. Early, guideline-concordant primary care engagement is essential to mitigate these risks and optimize long-term outcomes. Contemporary antiretroviral therapy (ART) recommendations from major panels provide multiple highly effective, well-tolerated options that enable durable viral suppression when initiated promptly and supported over time.

Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age-related macular degeneration (nAMD), addressing the significant burden associated with frequent anti-vascular endothelial growth factor (VEGF) injections. The inhibition of tyrosine kinases blocks the activation of VEGF receptor and platelet-derived growth factor receptor, thereby reducing angiogenesis and vascular leakage. Unlike current anti-VEGF agents that act extracellularly, TKIs target intracellular pathways, providing a complementary mechanism of action. Sustained-release TKI implants have demonstrated extended durability in clinical trials, potentially reducing treatment frequency and improving adherence. Ongoing studies have shown efficacy comparable to traditional therapies, with fewer injections and no significant adverse events. In this CE activity, expert faculty identify the challenges associated with anti-VEGF use in patients with nAMD, describe the rationale for targeting tyrosine kinases, and review the most recent clinical data on TKIs for treating nAMD.